I Hate Dialysis Message Board
Dialysis Discussion => Dialysis: News Articles => Topic started by: okarol on January 08, 2007, 01:48:37 PM
-
Genzyme kidney drug shows promise in trial
Monday January 8, 10:35 am ET
bizjournals.com
Genzyme Corp. said Monday new data reveals dialysis patients who took the company's kidney drug Rengal had a much lower death rate than patients who took another treatment.
The Cambridge, Mass., biotech company (Nasdaq: GENZ - News) said patients using Renagel experienced a significantly lower rate of death compared with patients using calcium-based phosphate binders in a newly completed study. The results were drawn from a randomized, open-label trial involving 127 patients at five dialysis centers in the United States.
In the study, patients new to dialysis randomly received either Renagel or a calcium-based phosphate binder, and were followed for an average of 44 months of treatment. Over the treatment period, 34 deaths occurred among study participants, including 23 patients who were using calcium-based binders and 11 who were using Renagel.
The results were published in the online version of Kidney International.
Published January 8, 2007 by the Boston Business Journal
URL http://biz.yahoo.com/bizj/070108/1399476.html?.v=2
-
Sounds a bit fishy to me.
http://www.genzyme.com/corp/media/petition1pagefinal.pdf